The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Kite/Gilead
Stock and Other Ownership Interests - Gilead Sciences
 
Speakers' Bureau - Kite/Gilead
Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma.
 
Frederick Lundry Locke
Honoraria - Kite, a Gilead company
Consulting or Advisory Role - Cellular Biomedicine Group
Research Funding - FORMA Therapeutics; Kite, a Gilead company
Patents, Royalties, Other Intellectual Property - Survivin Vaccine Patent
 
Armin Ghobadi
No Relationships to Disclose
 
Lazaros J. Lekakis
No Relationships to Disclose
 
David Bernard Miklos
Honoraria - Sanofi; Sanofi
Consulting or Advisory Role - Adaptive Biotechnologies; Kite, a Gilead company; Pharmacyclics/Janssen
Research Funding - Kite, a Gilead company; Novartis; Pharmacyclics; Roche/Genentech
Travel, Accommodations, Expenses - Adaptive Biotechnologies; Kite, a Gilead company; Pharmacyclics/Janssen; Sanofi
 
Caron A. Jacobson
Consulting or Advisory Role - Kite/Gilead; Pfizer; Pharmacyclics; Pharmacyclics
Speakers' Bureau - Cowen
 
Eric D. Jacobsen
Consulting or Advisory Role - Janssen; Merck; Seagen
Research Funding - Celgene
Travel, Accommodations, Expenses - Merck
 
Ira Braunschweig
Stock and Other Ownership Interests - Kite/Gilead (I)
Honoraria - Kite/Gilead
 
Olalekan O. Oluwole
Consulting or Advisory Role - Kite/Gilead
 
Tanya Siddiqi
Consulting or Advisory Role - Juno Therapeutics
Speakers' Bureau - Pharmacyclics/Janssen; Seagen
Research Funding - Acerta Pharma (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); TG Therapeutics (Inst)
Travel, Accommodations, Expenses - Juno Therapeutics; Kite, a Gilead company
 
Yi Lin
No Relationships to Disclose
 
Patrick Michael Reagan
Research Funding - Seagen
 
Umar Farooq
Research Funding - Kite, a Gilead company (Inst)
Travel, Accommodations, Expenses - Kite, a Gilead company
 
Abhinav Deol
Consulting or Advisory Role - Janssen; Kite/Gilead; Novartis
Research Funding - Bristol-Myers Squibb
 
Adrian Bot
Employment - Kite/Gilead
Stock and Other Ownership Interests - Gilead Sciences
 
John M. Rossi
No Relationships to Disclose
 
Yizhou Jiang
Employment - Kite/Gilead
Stock and Other Ownership Interests - Gilead Sciences
 
Allen Xue
Employment - Kite/Gilead
Stock and Other Ownership Interests - Amgen; Gilead Sciences
 
William Y. Go
Employment - Kite/Gilead
Stock and Other Ownership Interests - Gilead Sciences
 
Sattva Swarup Neelapu
Consulting or Advisory Role - Celgene; Kite, a Gilead company; Merck Sharp & Dohme; Novartis; Unum Therapeutics
Research Funding - Acerta Pharma; Bristol-Myers Squibb; Celgene; Cellectis; Kite, a Gilead company; Merck Sharp & Dohme; Pharmacyclics; poseida therapeutics
Travel, Accommodations, Expenses - Dava Oncology